相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU
Elena Sultova et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2021)
Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
Severin Rodler et al.
EUROPEAN JOURNAL OF CANCER (2021)
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
Peter Horak et al.
CANCER DISCOVERY (2021)
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Cancer patients' expectations when undergoing extensive molecular diagnostics-A qualitative study
Amy Rohrmoser et al.
PSYCHO-ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up
M. Heuser et al.
ANNALS OF ONCOLOGY (2020)
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
Tanios S. Bekaii-Saab et al.
FUTURE ONCOLOGY (2020)
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers
Paul Riviere et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
Shumei Kato et al.
NATURE COMMUNICATIONS (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy
Louisa von Baumgarten et al.
THERANOSTICS (2020)
Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board
Erica B. Bernhardt et al.
PRACTICAL LABORATORY MEDICINE (2020)
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options
Michael Bitzer et al.
JCO PRECISION ONCOLOGY (2020)
Molecular screening to select therapy for advanced cancer?
I. F. Tannock et al.
ANNALS OF ONCOLOGY (2019)
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
O. Tredan et al.
ANNALS OF ONCOLOGY (2019)
Variant classification in precision oncology
Jonas Leichsenring et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
The evidence framework for precision cancer medicine
Jeffrey A. Moscow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
Challenging Standard-of-Care Paradigms in the Precision Oncology Era
Vivek Subbiah et al.
TRENDS IN CANCER (2018)
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
Loic Verlingue et al.
EUROPEAN JOURNAL OF CANCER (2017)
Precision oncology based on omics data: The NCT Heidelberg experience
Peter Horak et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
Precision Oncology: Between Vaguely Right and Precisely Wrong
Amy Brock et al.
CANCER RESEARCH (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms AMeta-analysis
Maria Schwaederle et al.
JAMA ONCOLOGY (2016)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Maria Schwaederle et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center
Laura J. Tafe et al.
ONCOLOGIST (2015)
Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience
Maria Schwaederle et al.
ONCOLOGIST (2014)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
分享论文
